Comparison of Four Cisplatin-Based Radiochemotherapy Regimens for Nonmetastatic Stage III/IV Squamous Cell Carcinoma of the Head and Neck

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review

“…There were 1 prospective and 6 retrospective studies reporting on 48 to 264 patients (median = 94). In 6 studies, chemoradiotherapy was used as definitive treatment, although in 3 of these, a small number were treated postoperatively . In 1 study, all patients had postoperative chemoradiotherapy .…”

“…Another rationale for more frequent administration of cisplatin would be to provide radiosensitizing chemotherapy during a larger proportion of the course of radiotherapy . Retrospective comparisons of the efficacy, acute toxicity, and compliance of weekly and 3‐week cisplatin schedules reported conflicting results . However, a modeling study by Marcu et al, showed that daily administration of cisplatin with radiotherapy is more efficient than weekly cisplatin, increasing tumor control by 35% and 6%, respectively, as compared to radiotherapy alone.…”

Impact of feeding tube choice on severe late dysphagia after definitive chemoradiotherapy for human papillomavirus–negative head and neck cancer

“…Tumor site and T classification were also controlled for despite not showing a significant difference between the cohorts (Table ). Although single‐agent cisplatin was more commonly used with the NG approach given patterns of practice at our institution, late toxicity is not known to be significantly different between single‐agent cisplatin and multiagent cisplatin/5‐FU . Also, speech therapy use was not standardized in this cohort, although our reactive approach did not change significantly over the study period.…”

Degree of nephrotoxicity after intermediate‐ or high‐dose cisplatin‐based chemoradiotherapy in patients with locally advanced head and neck cancer

“…Both Espeli et al and our group showed that there was a higher incidence of chronic kidney injury in the high‐dose cisplatin schedule. In a retrospective study comparing 4 different chemoradiotherapy regimes in patients with locally advanced head and neck cancer, renal function was evaluated using the CTCAE version 2.0 (similar to CTCAE version 3.0 in creatinine increase) . They found a significant difference in grade 3 nephrotoxicity between patients treated with cisplatin 100 mg/m 2 on days 1, 22, and 43 and cisplatin 20 mg/m 2 on days 1 to 5 and 29 to 33 of 8% versus 1% ( p = .02).…”